We are pleased to invite investors and analysts to participate in our virtual event on Sunday, 16 June 2024, to highlight Ph III STARGLO results in 2L+ DLBCL presented during the EHA congress and provide an update in non-malignant hematology.   13:00 – 14:00 CEST / 12:00 – 13:00 BST 07:00 – 08:00 am EDT / 04:00 – 05:00 am PDT   The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 12:00 CEST on the day of the event. > click here   Access to virtual event (pre-registration required) Please pre-register for our webinar here*.   Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.   A replay of the webcast will be available via > ir.roche.com   *privacy notice     Best regards,
Bruno Eschli Head of Investor Relations	Rishard Salie Investor Relations Officer

Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com
Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

get the latest news and updates to your inbox.